

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

Panc 03.27

RRID:CVCL_1635

Type: Cell Line

Proper Citation

RRID:CVCL_1635

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1635

Proper Citation: RRID:CVCL_1635

Description: Cell line Panc 03.27 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: [PMID:9612602](#), [PMID:14695172](#), [PMID:16912165](#), [PMID:18000365](#), [PMID:19305140](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Johns Hopkins University School of Medicine; Baltimore; USA., Part of: TCGA-110-CL cell line panel., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Panc 03.27

Synonyms: Panc 3.27, Panc-03.27, PANC-03-27, Panc_03_27, Panc-3_27, PANC3.27, Panc3.27, Panc3_27, Panc-327, PANC 327, Panc327, PANC0327, Panc0327, PL11, PL-11

Cross References: CLO:CLO_0008376, EFO:EFO_0006467, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2549, BioGRID_ORCS_Cell_line:188, BioSample:SAMN03473169, BioSample:SAMN10988317, cancercellines:CVCL_1635, Cell_Model_Passport:SIDM01138, ChEMBL-Cells:ChEMBL3308124, ChEMBL-Targets:ChEMBL1075557, Cosmic:925346, Cosmic:949522, Cosmic:1198222, Cosmic:2434102, Cosmic-CLP:925346, DepMap:ACH-000139, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:925346, GEO:GSM206528, GEO:GSM621904, GEO:GSM784705, GEO:GSM887496, GEO:GSM888578, GEO:GSM1024407, GEO:GSM1374811, GEO:GSM1670332, IARC_TP53:27226, LiGeA:CCLE_371, LINCS_LDP:LCL-1740, PharmacDB:Panc03_27_1241_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_1635, PubChem_Cell_line:CVCL_1635, Wikidata:Q54937517

ID: CVCL_1635

Record Creation Time: 20220427T221408+0000

Record Last Update: 20260829T235540+0000

Ratings and Alerts

No rating or validation information has been found for Panc 03.27.

No alerts have been found for Panc 03.27.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Deng X, et al. (2026) RBM15-Mediated m6A Modification Regulates Proliferation and Migration of Pancreatic Cancer Cells via the lncRNA LINC01320/miR-1287-5p/FBXO11 Axis. *Biomolecules & therapeutics*, 34(3), 618.

Wang S, et al. (2025) IFN- γ -driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. *Nature communications*, 16(1), 10733.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. *Nature communications*, 16(1), 4866.

Yang S, et al. (2024) The GATOR2 complex maintains lysosomal-autophagic function by inhibiting the protein degradation of MiT/TFEs. *Molecular cell*, 84(4), 727.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. *Cell reports. Medicine*, 4(4), 101007.

Paul MC, et al. (2023) Non-canonical functions of SNAIL drive context-specific cancer progression. *Nature communications*, 14(1), 1201.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(23), 5190.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. *Cell reports*, 38(2), 110236.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.

Banh RS, et al. (2020) Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer. *Cell*, 183(5), 1202.

Shukla SK, et al. (2017) MUC1 and HIF-1 α Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. *Cancer cell*, 32(1), 71.